Quick definition: what is AOD-9604?
- Peptide based on the growth hormone fragment 176–191, engineered to focus on fat-metabolism pathways.
- Studied as an anti-obesity drug candidate; not an approved weight-loss medicine.
- Claims: promote lipolysis (fat breakdown) and reduce lipogenesis (fat storage) without raising IGF‑1.
- Human evidence: mixed and generally did not show clinically meaningful weight loss vs placebo in short‑term trials.
- Legal status in Australia: context‑dependent; see our legal overview for current rules.
How AOD-9604 is meant to work (theory vs data)
AOD-9604 was designed to mimic a specific region of growth hormone thought to influence fat metabolism, aiming to:
- Increase lipolysis (mobilising stored fat), and
- Reduce lipogenesis (creating new fat), particularly in adipose tissue.
Animal and cell studies have reported fat‑loss signals. However, these preclinical findings do not guarantee meaningful outcomes in humans. In clinical settings, translating biochemical signals into sustained, clinically significant weight loss has proven challenging.
What human studies show so far
- Randomised trials in adults with obesity generally did not demonstrate significant weight loss compared with placebo over 12–16 weeks.
- Some metabolic markers hinted at activity, but primary weight endpoints were not met consistently.
- Short‑term tolerability was reported as acceptable; long‑term effects and clinically relevant outcomes remain insufficiently established.
- Because efficacy was not convincingly demonstrated, AOD‑9604 did not progress to become an approved anti‑obesity medicine.
Forms and delivery people encounter
- Oral capsules: used in clinical studies.
- Injections and creams: commonly marketed, but real‑world quality, dosing accuracy and absorption can vary.
- Compounded products: rules are evolving in Australia; consult current guidance.
If someone is considering AOD‑9604 despite uncertain efficacy, product quality, dosing, supervision, and legal compliance are critical issues to understand first.
Safety, side effects and unknowns
Short‑term studies generally described AOD‑9604 as well tolerated, with reported effects such as headache, mild gastrointestinal upset or injection‑site irritation (when injected). Key unknowns remain:
- Long‑term safety and outcomes.
- Consistency and purity of non‑approved or compounded products.
- Use alongside other fat‑loss drugs or supplements.
AOD‑9604 is not an approved weight‑loss medicine. Individuals with medical conditions, those on prescription medications, and athletes subject to anti‑doping rules should seek qualified advice first.
How it compares to approved weight‑loss medicines
Approved weight‑loss options in Australia, such as GLP‑1–based therapies, have robust human data and defined prescribing frameworks. In contrast, AOD‑9604’s human evidence for meaningful weight loss is limited.
- GLP‑1 Australia Guide (Semaglutide, Tirzepatide overview)
- Weight Loss Injections in Australia (evidence, eligibility and access)
- AOD‑9604 vs Semaglutide
- AOD‑9604 vs Tirzepatide
Australian legal and sporting notes
- Regulatory status changes over time and varies by context (prescription, compounding, import/supply).
- AOD‑9604 is not an approved anti‑obesity medicine in Australia.
- Athletes: anti‑doping rules depend on current WADA/ASADA codes and whether a substance is approved; always confirm before use.
For current specifics on scripts, compounding limits and supply rules, see: Is AOD‑9604 Legal in Australia?
Common reasons people search for AOD‑9604
People often look up AOD‑9604 for stubborn belly fat, metabolism concerns, or as a “lighter” alternative to approved weight‑loss medicines. If that’s your goal, these explainers can help set expectations:
Frequently asked questions
What is AOD-9604 in simple terms?
AOD‑9604 is a modified fragment of human growth hormone (176–191) developed to target fat metabolism pathways. It is not an approved weight‑loss medicine.
Does AOD-9604 burn fat?
Preclinical studies suggested fat‑loss effects, but human trials generally did not show meaningful weight loss vs placebo over 12–16 weeks.
Is AOD-9604 the same as “fragment 176–191”?
They’re closely related. AOD‑9604 is based on GH fragment 176–191 with modifications to improve stability and activity.
Does AOD-9604 raise IGF‑1?
Available clinical data did not show significant increases in IGF‑1, unlike full growth hormone. Long‑term metabolic effects remain uncertain.
What forms are available?
Research used oral capsules. Commercial markets also offer injections and creams, but quality and absorption can vary and are not well established.
Is AOD-9604 legal to buy in Australia?
It depends on the context (prescription, compounding, import/supply). See: Is AOD‑9604 Legal in Australia?
Is AOD-9604 allowed for athletes?
Rules depend on current anti‑doping codes and approval status. Confirm with WADA/ASADA or your sport’s medical officer before use.
What should I consider instead?
Evidence‑based options include GLP‑1 or dual‑agonist therapies under medical supervision. See the GLP‑1 Australia Guide and Weight Loss Injections Australia.
Get help with AOD-9604 questions
Send your question and we’ll reply with evidence‑based guidance. No spam. No sales pressure.
Key takeaway
AOD‑9604 is a growth hormone–derived fragment designed to target fat metabolism, but human trials have not shown consistent, clinically meaningful weight loss. Consider the strength of evidence, legal status and safer, approved options before making decisions.